Market cap
$9 Mln
Revenue (TTM)
$25 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-37 Mln
-
ROE
-13.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.6
-
Debt to Equity
-3.2
-
Book Value
$--
-
EPS
$-1.3
-
Face value
--
-
Shares outstanding
29,000,100
8 Years Aggregate
CFO
€-92.03 Mln
EBITDA
€-102.03 Mln
Net Profit
€-184.76 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Centogene N.V. - ADR
| -55.4 | -58.1 | -58.6 | -81.3 | -65.3 | -65.8 | -- |
|
BSE Sensex*
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Centogene N.V. - ADR
| 29.0 | -82.2 | -51.5 | 7.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Centogene N.V. - ADR
|
0.1 | 9.4 | 48.5 | -35.5 | -117.5 | 397.6 | -- | 0.9 |
| 0.1 | 3.0 | 0.9 | -70.0 | -7,823.0 | -241.9 | -- | 0.1 | |
| 4.7 | 1,049.3 | 510.5 | 193.6 | -21.7 | 25.5 | 7 | 1.0 | |
| 2.3 | 309.5 | 0.0 | -39.1 | 281,529.0 | -41.7 | -- | 1.8 | |
| 1.7 | 45.8 | 5.0 | -23.3 | -442.3 | -121 | -- | 3.6 | |
| 37.0 | 2,546.3 | 0.0 | -171.6 | -- | -60 | -- | 7.3 | |
| 2.3 | 330.2 | 18.5 | -42.3 | -230.0 | -65.7 | -- | 3.5 |
Shareholding Pattern
View DetailsAbout Centogene N.V. - ADR
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and... pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany. Read more
-
CEO & Member of Management Board
Ms. Kim Stratton
-
CEO & Member of Management Board
Ms. Kim Stratton
-
Headquarters
Rostock
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Centogene N.V. - ADR
What is the current share price of Centogene NV - ADR Today?
The share price of Centogene NV - ADR is $0.06 (NASDAQ) as of 11-Aug-2025 09:30 EDT. Centogene NV - ADR has given a return of -65.25% in the last 3 years.
What is the current PB & PE ratio of Centogene NV - ADR?
Since, TTM earnings of Centogene NV - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-0.94 |
-1.33 |
2022 |
-- |
-- |
2021 |
-2.65 |
4.49 |
2020 |
-10.02 |
3.30 |
2019 |
-9.59 |
3.34 |
What is the 52 Week High and Low of Centogene NV - ADR?
The 52-week high and low of Centogene NV - ADR are Rs -- and Rs -- as of 28-Aug-2026.
What is the market cap of Centogene NV - ADR?
Centogene NV - ADR has a market capitalisation of $ 9 Mln as on 11-Aug-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Centogene NV - ADR?
Before investing in Centogene NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.